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Type of tissue Source Stem cell culture condition (niche factors) Differentiation culture condition
Stomach
Adult mouse EGF, Noggin, R-spondin, Wnt-3A, FGF10 EGF, R-spondin
Adult human EGF, Noggin, R-spondin, Wnt-3A, FGF10 EGF, R-spondin
hPSC EGF EGF
Small intestine
Adult mouse EGF, Noggin, R-spondin EGF, Noggin, R-spondin
Adult human EGF, Noggin, R-spondin, Wnt-3A TGF-b inhibitor, p38 inhibitor EGF, Noggin, R-spondin, TGF-b inhibitor
hPSC EGF EGF
Colon
Adult mouse EGF, Noggin, R-spondin, Wnt-3A EGF, Noggin, R-spondin
Adult human EGF, Noggin, R-Spondin, Wnt-3A, TGF-b inhibitor, p38 inhibitor EGF, Noggin, R-spondin, TGF-b inhibitor
Pancreas
Adult mouse EGF, Noggin, R-spondin, Wnt-3A, FGF10, Nicotinamide EGF, Noggin, R-spondin, Wnt-3A
Adult human EGF, Noggin, R-spondin, Wnt-3A, FGF10, TGF-b inhibition, Nicotinamide Not reported
Liver
Adult mouse EGF, Noggin, R-spondin, Wnt-3A, FGF10, HGF, Nicotinamide EGF, Noggin, FGF10, TGF-b inhibition, Notch inhibition
Adult human EGF, Noggin, R-spondin, Wnt-3A, FGF10, HGF, Nicotinamide, TGF-b inhibi-tor, Forskolin
EGF, Noggin, FGF10, TGF-b inhibition, Notch inhibition, 
BMP7
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Tissue stem cells require unique niche microenvironments. In the presence of specific combinations of niche factors, mouse and human epithelial tissues from stomach, small
intestine, colon, pancreas duct, and liver bile duct efficiently form stereotypic organoids. The platform of epithelial organoids can also be employed for in vitro generation of
digestive tissue from human pluripotent stem cells. Organoids hold great promise for basic and translational research.
Adult Tissue-Derived Epithelial Organoids
“Mini-gut” organoids are stereotypic tissue-like structures derived from digestive organs. The mini-gut organoid culture system was originally established from mouse 
small intestinal crypts (Sato et al., 2009). The technology was subsequently adapted for other digestive epithelial tissues, such as the epithelium of stomach, colon, pancreas 
ducts, and liver bile ducts (Barker et al., 2010; Boj et al., 2015; Huch et al., 2013; Sato et al., 2011a). Lgr5+ gut epithelial stem cells or Lgr5− duct epithelium initially form sym-
metric cyst structures, which then generate “budding structures.” The budding structures resemble intestinal crypts (intestine) or regenerating duct epithelial structures (liver, 
pancreas) consisting of Lgr5+ stem cells flanked by differentiated daughter cells. In small intestinal organoids, Lgr5+ stem cells receive niche signals from the neighboring 
differentiated Paneth cells for their self-renewal (Sato et al., 2011b).
Single epithelial cells can form organoids in 7–10 days, which can be dissociated into single cells to reinitiate organoid formation. Mini-gut organoids can be indefinitely 
propagated through such passaging in the presence of optimal niche factors.
In the mini-gut culture system, the culture condition for each tissue stem cell recapitulates niche microenvironments from which the stem cells originate. Adult tissue-
derived epithelial organoids require generic niche factors such as laminin-rich extracellular matrix (Matrigel), EGF, Noggin, and R-spondin. Wnt ligand is required for organoids 
that secrete insufficient levels of autocrine or paracrine Wnt ligands. Each tissue stem cell type often requires additional tissue-specific niche factors, such as TGF-β inhibitor, 
FGF10, and/or HGF, as summarized in the table. Mouse small intestinal organoids self-renew and produce all types of epithelial cells in the standard culture condition, while 
the other organoid types require withdrawal of certain niche factors in order to differentiate.
Human Pluripotent Stem-Cell-Derived Organoids
Human pluripotent stem cells (hPSCs) differentiate into definitive endoderm upon activin A stimulation. The hPSC-derived definitive endoderm can further differentiate into 
hindgut endoderm with Wnt3A and FGF4 or into posterior foregut with Wnt-3A, FGF4, Noggin, and Retinoic acid. The hindgut epithelium is transferred to mini-gut organoid 
culture conditions to form intestinal organoids (Spence et al., 2011). Unlike Lgr5 stem-cell-derived organoids, hPSC-derived organoids harbor niche factor-producing mes-
enchymal cells that mitigate niche factor requirements. Although hPSC-derived intestinal organoids display fetal intestine-like immature properties, they undergo complete 
differentiation upon transplantation into the kidney subcapsule of mice.
hPSC-derived posterior foregut epithelium undergoes antral specification in the presence of EGF, Noggin, and retinoic acid. The antrum epithelium forms human gastric 
organoids (hGOs) upon transfer into Matrigel with high concentrations of EGF. hGOs possess all types of differentiated antral epithelial cells (McCracken et al., 2014). These 
hPSC-derived small intestinal or gastric organoids may provide insights into the generation of other foregut tissue organoids, such as gastric fundus, lungs, and pancreas.
Translational Application of Mini-Gut Organoids
The organoid culture system is applicable to basic and translational research. Established organoids can be engrafted onto injured intestinal mucosa. Furthermore, liver 
ductal organoids differentiate into functional hepatocytes upon transplantation. The expanded human liver organoids show robust chromosomal stability and very low rates of 
single base changes, making the organoids a safe cell source for regenerative medicine (Huch et al., 2015).
Mini-gut organoids have been applied for disease modeling of genetic diseases, such as cystic fibrosis, a1-antitrypsin deficiency, and Alagille syndrome (Huch et al., 2015; 
Schwank et al., 2013). These organoids phenocopy clinical traits. Interestingly, mutations in CFTR gene in organoids from cystic fibrosis confer resistance against cAMP-
dependent ballooning of organoids, which offers a simple functional diagnostic tool. Furthermore, CRISPR-Cas9-based gene correction can restore the cAMP responsiveness
of organoids, raising a possibility of organoid-based gene therapy (Schwank et al., 2013).
The mini-gut culture system can be applied to cancer tissue, such as stomach, colorectal, pancreas, and prostate cancer. During tumorigenesis, niche factors often 
become dispensable, leading to a less stringent culture condition for cancer organoids as compared to wild-type organoids. Established cancer organoids can be xeno-trans-
planted to recapitulate histopathology of the parental tumor from which they are derived. Cancer organoids reflect genetic lesions and gene expression patterns, opening up 
a possibility of in vitro drug testing for the prediction of clinical treatment response in patients. Biobanking of organoids derived from diseased tissues will help to unravel the 
pathogenesis of disease and the development of new diagnostic tools and new drugs.
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